No headlines found.
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
Globe Newswire (Wed, 12-Aug 4:01 PM ET)
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
Arrivent Biopharma trades on the NASDAQ stock market under the symbol AVBP.
As of August 25, 2026, AVBP stock price climbed to $30.56 with 308,615 million shares trading.
AVBP has a beta of 1.00, meaning it tends to be more sensitive to market movements. AVBP has a correlation of 0.07 to the broad based SPY ETF.
AVBP has a market cap of $1.51 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that AVBP belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
AVBP has outperformed the market in the last year with a return of +52.0%, while the SPY ETF gained +19.7%. In the last 3 month period, AVBP beat the market returning +14.3%, while SPY returned +2.9%. However, in the most recent 2 weeks AVBP has underperformed the stock market by returning -1.4%, while SPY returned -1.0%.
AVBP support price is $27.30 and resistance is $29.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVBP shares will trade within this expected range on the day.
